Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer

Table 2 Univariate and multivariate analyses of the likelihood of early tumor response 1 month after SABR

Factors	OR	95% CI	P
CD8+CD28+ T
Low	Reference
High	0.12	0.03–0.48	0.003
CD8+CD28+ T (adjusted)	0.19	0.04–0.90	0.037
CD8+CD28− T
Low	Reference
High	1.83	0.61–5.47	0.277
Treg
Low	Reference
High	1.65	0.49–5.46	0.412
CD4+ T
Low	Reference
High	0.54	0.18–1.62	0.277
CD4/Treg ratio
Low	Reference
High	0.24	0.06–0.90	0.035
CD4/Treg ratio (adjusted)	0.25	0.06–1.05	0.059
CD8+ T
Low	Reference
High	1.00	0.34–2.92	1.000
CD8/Treg ratio
Low	Reference
High	0.79	0.24–2.59	0.704
CD8/CD4 ratio
Low	Reference
High	0.74	0.25–2.17	0.585
Age	1.03	0.98–1.09	0.140
Sex
Female	Reference
Male	0.97	0.31–3.03	0.960
Primary T stage
T1	Reference
T2–4	1.05	0.32–3.47	0.931
Primary N stage
N0	Reference
N1–3	1.26	0.38–4.12	0.699
Primary stage
I	Reference
II–III	2.66	0.53–13.18	0.229
Histology
SCC	Reference
AD	1.26	0.43–3.69	0.672
Performance status
0	Reference
1–2	0.85	0.29–2.50	0.778
Smoking history
Non-smoker	Reference
Smoker	0.57	0.19–1.70	0.318
Metastatic status
Isolated lung metastasis	Reference
Multiple metastasis	1.66	0.51–5.38	0.393
The diameter of targeted lung metastases	0.98	0.64–1.49	0.932
BED₁₀	0.91	0.84–0.99	0.032
BED₁₀ (adjusted)	0.90	0.80–1.02	0.109

ISSN: 1479-5876